|Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA||MD, CEO & Director||243,98k||N/A||N/A|
|Pablo Neyertz||Director of Finance||106,55k||N/A||N/A|
|Associate Prof. Hassan Bakos||Director of Operations||145,07k||N/A||N/A|
|Prof. R. John Aitken Ph.D., ScD FRSE||Scientific Director||152,2k||N/A||N/A|
|Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD||Company Secretary||N/A||N/A||N/A|
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Memphasys Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.